Marianna Fontana
YOU?
Author Swipe
View article: Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial Open
Background: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive disease caused by the deposition of transthyretin as amyloid in the myocardium. Current therapies may slow disease progression but do not clear existing d…
View article: Transthyretin amyloid cardiomyopathy: from cause to novel treatments
Transthyretin amyloid cardiomyopathy: from cause to novel treatments Open
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disorder marked by amyloid deposition in the heart, ultimately impairing cardiac function. Recent treatment advances have paralleled an evolving understanding of ATTR-CM patho…
View article: Peripheral Neuropathy in p.Val142Ile (Val122Ile) Variant Hereditary Transthyretin-Mediated Amyloidosis
Peripheral Neuropathy in p.Val142Ile (Val122Ile) Variant Hereditary Transthyretin-Mediated Amyloidosis Open
Real-world experience from the UK national cohort of p.V142I ATTRv indicates that peripheral neuropathy is of a mild severity and less frequent than previously reported.
View article: Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment
Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment Open
Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases and is characterized by phenotypical heterogeneity with a high prevalence of multiple, often overlapping cardiometabolic disorders. …
View article: Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial
Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial Open
View article: Uncertain Clinical Relevance of Serial Bone Scintigraphy Findings in Treated Transthyretin Amyloid Cardiomyopathy
Uncertain Clinical Relevance of Serial Bone Scintigraphy Findings in Treated Transthyretin Amyloid Cardiomyopathy Open
Our study indicates a poor correlation between reduction in 99mTc-DPD uptake at follow-up and numerous established biomarkers of ATTR-CM treatment response. Changes in DPD uptake in ATTR-CM patients receiving DMT should be inter…
View article: A retrospective study of isatuximab-pomalidomide-dexamethasone in relapsed/refractory systemic AL amyloidosis
A retrospective study of isatuximab-pomalidomide-dexamethasone in relapsed/refractory systemic AL amyloidosis Open
Not available.
View article: Prognostic Value of Malnutrition, Frailty, and Physical Performance in Transthyretin Cardiac Amyloidosis: Insights From a Prospective Multicenter Cohort Study
Prognostic Value of Malnutrition, Frailty, and Physical Performance in Transthyretin Cardiac Amyloidosis: Insights From a Prospective Multicenter Cohort Study Open
BACKGROUND: The prevalence of transthyretin cardiac amyloidosis among older adults (often octogenarians) is increasing. We aimed to determine whether age and geriatric syndromes bear any impact on the management and outcomes in transthyret…
View article: Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis
Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis Open
Background and Aims Concomitant aortic stenosis (AS) and transthyretin-associated cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of structural heart failure. Aortic valve replacement (AVR) improves prognosis in this popu…
View article: Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: a plain language summary
Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: a plain language summary Open
What is this summary about?
View article: Frailty, disability, and malnutrition assessment for preventive measure in transthyretin cardiac amyloidosis
Frailty, disability, and malnutrition assessment for preventive measure in transthyretin cardiac amyloidosis Open
Background The prevalence of transthyretin cardiac amyloidosis (ATTR-CA) among older adults is increasing. Whether age and geriatric syndromes bear any impact on the management and outcomes in ATTR-CA is poorly understood. Methods In a pro…
View article: Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis
Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis Open
The demographics of patients with transthyretin amyloidosis with cardiomyopathy have evolved over the past decade, mostly driven by improved awareness of the disease among clinicians, noninvasive imaging tools for diagnosis, and new, effec…
View article: Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis
Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis Open
Summary Systemic light chain (AL) amyloidosis is an incurable disorder caused by extra‐cellular deposition of light‐chain aggregates in critical organs. An immunomodulatory agent‐based quadruplet including anti‐CD38 therapy has not been in…
View article: Ethnicity in systemic AL amyloidosis may impact risk stratification
Ethnicity in systemic AL amyloidosis may impact risk stratification Open
Not available.
View article: Impact of age and sex on myocardial involvement in hospitalized COVID-19 patients: A Pre-specified Subanalysis of COVID-heart
Impact of age and sex on myocardial involvement in hospitalized COVID-19 patients: A Pre-specified Subanalysis of COVID-heart Open
View article: Myocardial ischaemia following COVID-19: a cardiovascular magnetic resonance study
Myocardial ischaemia following COVID-19: a cardiovascular magnetic resonance study Open
The pathophysiology of myocardial injury following COVID-19 remains uncertain. COVID-HEART was a prospective, multicentre study utilising cardiovascular magnetic resonance (CMR) to characterise COVID-related myocardial injury. In this pre-…
View article: Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial Open
BACKGROUND: In the phase 3 randomized controlled study ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), acoramidis, a transthyretin stabilizer, demonstrated significant efficacy on the prima…
View article: Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy
Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy Open
View article: How to conduct clinical research in cardiovascular imaging: a primer for clinical cardiologists and researchers—a statement of the European Association of Cardiovascular Imaging (EACVI) of the ESC
How to conduct clinical research in cardiovascular imaging: a primer for clinical cardiologists and researchers—a statement of the European Association of Cardiovascular Imaging (EACVI) of the ESC Open
This statement from the European Association of Cardiovascular Imaging (EACVI) of the ESC aims to address the fundamental principles that guide clinical research in the field of cardiovascular imaging. It provides clinical researchers, car…
View article: Large Transthyretin Aggregates in Plasma of ATTR Amyloidosis Patients
Large Transthyretin Aggregates in Plasma of ATTR Amyloidosis Patients Open
[Figure: see text]
View article: Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Open
Among patients with ATTR-CM, treatment with vutrisiran led to a lower risk of death from any cause and cardiovascular events than placebo and preserved functional capacity and quality of life. (Funded by Alnylam Pharmaceuticals; HELIOS-B C…
View article: Clinical Significance of Myocardial Injury in Patients Hospitalized for COVID-19
Clinical Significance of Myocardial Injury in Patients Hospitalized for COVID-19 Open
Myocardial injury in severe hospitalized COVID-19 survivors is nonprogressive. Medium-term outcomes show a low incidence of major adverse cardiovascular events and improved quality of life. (COVID-19 Effects on the Heart; ISRCTN58667920).
View article: Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis
Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis Open
Importance Cardiac amyloid infiltration is the key determinant of survival in systemic light-chain (AL) amyloidosis. Current guidelines recommend early switching therapy in patients with a nonoptimal or suboptimal response regardless of th…
View article: Prognostic utility of exercise cardiovascular magnetic resonance in patients with systemic sclerosis-associated pulmonary arterial hypertension
Prognostic utility of exercise cardiovascular magnetic resonance in patients with systemic sclerosis-associated pulmonary arterial hypertension Open
Aims Systemic sclerosis complicated by pulmonary arterial hypertension (SSc-PAH) is a rare condition with poor prognosis. The majority of patients are categorized as intermediate risk of mortality. Cardiovascular magnetic resonance (CMR) i…
View article: Effect of beta‐blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta‐analysis
Effect of beta‐blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta‐analysis Open
Aims The efficacy of beta‐blockers in cardiac amyloidosis (CA) is unclear, and concerns persist that neurohormonal blockade could worsen symptoms of heart failure. We aimed to assess whether beta‐blocker therapy is associated with improved…
View article: Wild-type transthyretin cardiac amyloidosis: the need for a comprehensive geriatric assessment beyond age
Wild-type transthyretin cardiac amyloidosis: the need for a comprehensive geriatric assessment beyond age Open
editoriale
View article: Native myocardial T1 and right ventricular size by CMR predict outcome in systemic sclerosis-associated pulmonary hypertension
Native myocardial T1 and right ventricular size by CMR predict outcome in systemic sclerosis-associated pulmonary hypertension Open
Objectives Measures of right heart size and function are prognostic in systemic sclerosis-associated pulmonary hypertension (SSc-PH), but the importance of myocardial tissue characterisation remains unclear. We aimed to investigate the pre…
View article: Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis
Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis Open
View article: Inline AI: Open-source Deep Learning Inference for Cardiac MR
Inline AI: Open-source Deep Learning Inference for Cardiac MR Open
Cardiac Magnetic Resonance (CMR) is established as a non-invasive imaging technique for evaluation of heart function, anatomy, and myocardial tissue characterization. Quantitative biomarkers are central for diagnosis and management of hear…
View article: The changing landscape of heart failure treatment in transthyretin amyloid cardiomyopathy: Is the time ripe for clinical use of sodium–glucose cotransporter 2 inhibitors?
The changing landscape of heart failure treatment in transthyretin amyloid cardiomyopathy: Is the time ripe for clinical use of sodium–glucose cotransporter 2 inhibitors? Open
N/A